Canaccord Genuity Reiterates a 'Buy' on Anthera Pharma (ANTH); All Eyes on June Phase 2 Data
Tweet
Share
E-mailGet Alerts ANTH Hot Sheet
Price: $0.00 --0%
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
8 Buy, 3 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Anthera Pharma (NASDAQ: ANTH) price target of $6.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on blisibimod (B--mod) clinical and commercial potential in lupus. We expect that B-mod, ANTH’s BAFF peptibody for lupus, will yield positive data from the Phase 2 PEARL trial in June and that Anthera will start the Phase 3 Chablis trial in Q1/13. Anthera may start Phase 2 B-mod trials in other lupus-related B cell disorders to leverage market potential and diversify clinical risk."
"Future clinical and corporate strategy all hinges on PEARL data details and quality. Final design of the pivotal CHABLIS trial is extremely dependent on upcoming PEARL secondary endpoint data. We also think that the degree of clinical benefit reflected by both primary and second endpoints could greatly impact partnership and BD terms and timing."
For an analyst ratings summary and ratings history on Anthera Pharma click here. For more ratings news on Anthera Pharma click here.
Shares of Anthera Pharma closed at $1.75 yesterday.
Analyst, Ritu Baral, said, "Reiterate rating and price target on blisibimod (B--mod) clinical and commercial potential in lupus. We expect that B-mod, ANTH’s BAFF peptibody for lupus, will yield positive data from the Phase 2 PEARL trial in June and that Anthera will start the Phase 3 Chablis trial in Q1/13. Anthera may start Phase 2 B-mod trials in other lupus-related B cell disorders to leverage market potential and diversify clinical risk."
"Future clinical and corporate strategy all hinges on PEARL data details and quality. Final design of the pivotal CHABLIS trial is extremely dependent on upcoming PEARL secondary endpoint data. We also think that the degree of clinical benefit reflected by both primary and second endpoints could greatly impact partnership and BD terms and timing."
For an analyst ratings summary and ratings history on Anthera Pharma click here. For more ratings news on Anthera Pharma click here.
Shares of Anthera Pharma closed at $1.75 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Advance Auto Parts (AAP) PT Lowered to $48 at DA Davidson Following 25% Selloff Post Q2 Results
- DA Davidson Starts Comfort Systems USA (FIX) at Buy
- DA Davidson Starts Everus (ECG) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
